Sanofi was founded in 2004 and is headquartered in Paris, FR
Report incorrect company information
Key People/Management at Sanofi
Olivier Brandicourt
CEO
Olivier Charmeil
Executive Vice President and General Manager
Jerome Contamine
Executive Vice President & Chief Financial Officer
Karen Linehan
Executive Vice President, Legal Affairs and General Counsel
David Loew
Executive Vice President and General Manager of Sanofi Pasteur
Philippe Luscan
Executive Vice President, Global Industrial Affairs
Report incorrect company information
Sanofi Office Locations
Sanofi has offices in Singapore, Paris, Bridgewater, Macquarie Park and in 9 other locations
Paris, FR (HQ)
54, rue La Boétie
Macquarie Park, AU
Building D, 12-24 Talavera Road
Ontario, CA
1755 Steeles avenue West
Beijing, CN
7th floor, n°112, Jian Guo Lu, Chaoyang District
Hong Kong, HK
Room 2504-2511, Windsor House, 311, Gloucester Road, Causeway Bay
New Delhi, IN
D-2, Fourth Floor, Southern Park, DDA Commercial Centre, Saket
Report incorrect company information
Sanofi Financials and Metrics
Sanofi Financials
Sanofi's revenue was reported to be €37.06 b in FY, 2015 which is a 9.7% increase from the previous period.
| EUR | |
|---|---|
Revenue (FY, 2015) | 37.1 b |
Revenue growth (FY, 2014 - FY, 2015), % | 9.7% |
Gross profit (FY, 2015) | 26.1 b |
Gross profit margin (FY, 2015), % | 70.5% |
Net income (FY, 2015) | 4.4 b |
Market capitalization (31-Oct-2017) | 102.1 b |
Closing share price (31-Oct-2017) | 81.6 |
Sanofi's current market capitalization is €102.1 b.
- Source: SEC Filings
| EUR | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
Revenue | 33 b | 33.8 b | 37.1 b |
Revenue growth, % | 2% | 10% | |
Cost of goods sold | 10.3 b | 10.2 b | 10.9 b |
Gross profit | 22.6 b | 23.5 b | 26.1 b |
- Source: SEC Filings
| EUR | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
Cash From Operating Activities | 6.4 b | 6.3 b | 7.2 b |
| EUR | Y, 2015 |
|---|---|
Revenue/Employee | 365.4 k |
Sanofi Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Ablynx | January 29, 2018 | $4.80 b |
| Bioverativ | January 22, 2018 | $11.60 b |
Report incorrect company information
